^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Meta10-19

    i
    Other names: Meta10-19, metabolically armed CD19 CAR-T
    Associations

    News

    Trials
    Company:
    Leman Biotech
    Drug class:
    CD19-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    12d
    Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research (clinicaltrials.gov)
    P1, N=36, Recruiting, The Children's Hospital of Zhejiang University School of Medicine
    New P1 trial • CAR T-Cell Therapy
    |
    cyclophosphamide • Meta10-19
    3ms
    Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research (clinicaltrials.gov)
    P1, N=18, Recruiting, Anhui Provincial Hospital
    New P1 trial
    |
    cyclophosphamide • Meta10-19
    6ms
    Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research (clinicaltrials.gov)
    P1, N=18, Recruiting, He Huang
    New P1 trial • CAR T-Cell Therapy
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD19 (CD19 Molecule) • BCL6 (B-cell CLL/lymphoma 6) • IL6 (Interleukin 6)
    |
    CD19 expression • BCL2 translocation
    |
    cyclophosphamide • Meta10-19
    1year
    Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10- 19) in the Treatment of r/r B-ALL Clinical Research (clinicaltrials.gov)
    P1, N=18, Recruiting, Anhui Provincial Hospital
    New P1 trial • CAR T-Cell Therapy
    |
    CD19 (CD19 Molecule)
    |
    CD19 expression
    |
    cyclophosphamide • Meta10-19
    1year
    Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research (clinicaltrials.gov)
    P1, N=18, Recruiting, Anhui Provincial Hospital | Not yet recruiting --> Recruiting
    Enrollment open • CAR T-Cell Therapy
    |
    CD19 (CD19 Molecule)
    |
    CD19 expression
    |
    cyclophosphamide • Meta10-19
    over1year
    Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, Anhui Provincial Hospital
    New P1 trial • CAR T-Cell Therapy
    |
    CD19 (CD19 Molecule)
    |
    CD19 expression
    |
    cyclophosphamide • Meta10-19